2C-B-DragonFLY
2C-B-DragonFLY, also known as 2C-B-DFLY, is a psychedelic drug of the phenethylamine, 2C, and FLY families.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
2C-B-DragonFLY, also known as 2C-B-DFLY, is a psychedelic drug of the phenethylamine, 2C, and FLY families. It is the "DragonFLY" (benzodifuran) analogue of 2C-B and 2C-B-FLY as well as the phenethylamine (α-desmethyl) analogue of Bromo-DragonFLY (DOB-DFLY).
Use and effects
The properties and effects of 2C-B-DragonFLY in humans do not appear to be known.
Pharmacodynamics
2C-B-DragonFLY's predicted affinity (K i ) for the serotonin 5-HT 2A receptor has been reported to be 26 nM. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. 2C-B-DragonFLY is about 2.2-fold more potent than 2C-B and about 1.7-fold more potent than 2C-B-FLY in terms of this effect.
On the other hand, it is about 5-fold less potent than Bromo-DragonFLY in producing the head-twitch response in rodents. These findings demonstrate the importance of the fully aromatic benzodifuran ring system for optimal serotonin 5-HT 2A receptor interaction, though 2C-B-DragonFLY is still considerably less potent than Bromo-DragonFLY.
Analogues
Analogues of 2C-B-DragonFLY include 2C-B, 2C-B-FLY, 2C-B-ButterFLY, and Bromo-DragonFLY (DOB-DFLY), among others.
History
2C-B-DragonFLY was first described in the scientific literature by 1999. Subsequently, its pharmacology was described by Adam Halberstadt and colleagues in 2019.
Canada
2C-B-DragonFLY is a controlled substance in Canada under phenethylamine blanket-ban language.
United States
2C-B-DragonFLY is not an explicitly controlled substance in the United States.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371211793 under CC BY-SA 4.0; modifications have been made.